SIFI and Avanzanite Bioscience’s Akantior (Polihexanide) Gains the EC’s Approval to Treat Acanthamoeba Keratitis (AK)
Shots:
-
Following recommendations from the EMA’s CHMP & COMP, the EC has approved Akantior to treat AK among adults & adolescents (≥12yrs.)
-
Approval was based on the data from P-III (ODAK) study in AK patients (n=135), published in Ophthalmology, demonstrating that the disease cured in 84.8%, full vision restoration was found in 66.7% with none of them requiring optical cornea transplant and 7.5% needed a therapeutic cornea transplant
-
Avanzanite received the exclusive commercialization rights of Akantior in European Economic Area and Switzerland as per an agreement b/w the company and SIFI
Ref: SIFI and Avanzanite Bioscience| Image: SIFI and Avanzanite Bioscience
Related News:- SIFI Reports the CHMP’s Positive Opinion of Akantior (Polihexanide) to Treat Acanthamoeba Keratitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
